Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes

American Journal of Cardiology

Volumn 120, Issue 1, 2017, Pages S17-S27

  Paneni, Francesco ^a   Lüscher, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DIABETIC PATIENT; GLYCEMIC CONTROL; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; AGONISTS; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 85020479674     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2017.05.015     Document Type: Article

References (77)

1. 1 Beckman, J.A., Paneni, F., Cosentino, F., Creager, M.A., Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 34 (2013), 2444–2452.
2. 2 Authors/Task Force Members, Ryden, L., Grant, P.J., Anker, S.D., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 (2013), 3035–3087.
3. 3 Malmberg, K., Yusuf, S., Gerstein, H.C., et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 102 (2000), 1014–1019.
4. 4 Haffner, S.M., Lehto, S., Ronnemaa, T., Pyorala, K., Laakso, M., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998), 229–234.
5. 5 Yahagi, K., Kolodgie, F.D., Lutter, C., et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arterioscler Thromb Vasc Biol 37:2 (2017), 191–204.
6. 6 Avogaro, A., Fadini, G.P., Sesti, G., Bonora, E., Del Prato, S., Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol, 15, 2016, 111.
7. 7 Low Wang, C.C., Hess, C.N., Hiatt, W.R., Goldfine, A.B., Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation 133 (2016), 2459–2502.
8. 8 Mellbin, L.G., Anselmino, M., Ryden, L., Diabetes, prediabetes and cardiovascular risk. Eur J Cardiovasc Prev Rehabil 17:suppl 1 (2010), S9–S14.
9. 9 Paneni, F., Beckman, J.A., Creager, M.A., Cosentino, F., Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 34 (2013), 2436–2443.
10. 10 Khaw, K.T., Wareham, N., Bingham, S., Luben, R., Welch, A., Day, N., Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 141 (2004), 413–420.
11. 11 The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44 (1995), 968–983.
12. 12 Derr, R., Garrett, E., Stacy, G.A., Saudek, C.D., Is HbA(1c) affected by glycemic instability?. Diabetes Care 26 (2003), 2728–2733.
13. 13 Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H.C., Miller, M.E., Byington, R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
14. 14 ADVANCE Collaborative Group, Patel, A., MacMahon, S., Chalmers, J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
15. 15 Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
16. 16 Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
17. 17 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998), 854–865.
18. 18 Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
19. 19 Holman, R.R., Sourij, H., Califf, R.M., Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 383 (2014), 2008–2017.
20. 20 Kooy, A., de Jager, J., Lehert, P., et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 169 (2009), 616–625.
21. 21 Johnson, J.A., Majumdar, S.R., Simpson, S.H., Toth, E.L., Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25 (2002), 2244–2248.
22. 22 Tzoulaki, I., Molokhia, M., Curcin, V., et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ, 339, 2009, b4731.
23. 23 Roumie, C.L., Hung, A.M., Greevy, R.A., et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 157 (2012), 601–610.
24. 24 Wheeler, S., Moore, K., Forsberg, C.W., et al. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia 56 (2013), 1934–1943.
25. 25 Boussageon, R., Supper, I., Bejan-Angoulvant, T., et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med, 9, 2012, e1001204.
26. 26 Lamanna, C., Monami, M., Marchionni, N., Mannucci, E., Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 13 (2011), 221–228.
27. 27 Tahrani, A.A., Barnett, A.H., Bailey, C.J., Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol 12 (2016), 566–592.
28. 28 Rendell, M., The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 64 (2004), 1339–1358.
29. 29 Meinert, C.L., Knatterud, G.L., Prout, T.E., Klimt, C.R., A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19:suppl (1970), 789–830.
30. 30 Scognamiglio, R., Avogaro, A., Vigili de Kreutzenberg, S., et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 51 (2002), 808–812.
31. 31 Viberti, G., Kahn, S.E., Greene, D.A., et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 25 (2002), 1737–1743.
32. 32 Ferrannini, E., DeFronzo, R.A., Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J 36 (2015), 2288–2296.
33. 33 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998), 837–853.
34. 34 Simpson, S.H., Majumdar, S.R., Tsuyuki, R.T., Eurich, D.T., Johnson, J.A., Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 174 (2006), 169–174.
35. 35 Morgan, C.L., Poole, C.D., Evans, M., Barnett, A.H., Jenkins-Jones, S., Currie, C.J., What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 97 (2012), 4605–4612.
36. 36 Marx, N., Rosenstock, J., Kahn, S.E., et al. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA). Diab Vasc Dis Res 12 (2015), 164–174.
37. 37 Yki-Jarvinen, H., Thiazolidinediones. N Engl J Med 351 (2004), 1106–1118.
38. 38 Loke, Y.K., Singh, S., Furberg, C.D., Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180 (2009), 32–39.
39. 39 Lipscombe, L.L., Gomes, T., Levesque, L.E., Hux, J.E., Juurlink, D.N., Alter, D.A., Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298 (2007), 2634–2643.
40. 40 Graham, D.J., Ouellet-Hellstrom, R., MaCurdy, T.E., et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304 (2010), 411–418.
41. 41 Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007), 2457–2471.
42. 42 Singh, S., Loke, Y.K., Furberg, C.D., Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298 (2007), 1189–1195.
43. 43 Cobitz, A., Zambanini, A., Sowell, M., et al. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone. Pharmacoepidemiol Drug Saf 17 (2008), 769–781.
44. 44 Home, P.D., Pocock, S.J., Beck-Nielsen, H., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373 (2009), 2125–2135.
45. 45 Dormandy, J.A., Charbonnel, B., Eckland, D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
46. 46 Kernan, W.N., Viscoli, C.M., Furie, K.L., et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374 (2016), 1321–1331.
47. 47 Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
48. 48 Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 iabetes. N Engl J Med 375 (2016), 1834–1844.
49. 49 Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
50. 50 Lincoff, A.M., Tardif, J.C., Schwartz, G.G., et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 311 (2014), 1515–1525.
51. 51 Zhong, J., Maiseyeu, A., Davis, S.N., Rajagopalan, S., DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res 116 (2015), 1491–1504.
52. 52 Scheen, A.J., Cardiovascular effects of gliptins. Nat Rev Cardiol 10 (2013), 73–84.
53. 53 Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
54. 54 Zannad, F., Cannon, C.P., Cushman, W.C., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385 (2015), 2067–2076.
55. 55 Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
56. 56 Paneni, F., DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety. Cardiovasc Diagn Ther 5 (2015), 471–478.
57. 57 Standl, E., Schnell, O., DPP-4 inhibitors and risk of heart failure EXAMINEd. Lancet 385 (2015), 2022–2024.
58. 58 Udell, J.A., Cavender, M.A., Bhatt, D.L., Chatterjee, S., Farkouh, M.E., Scirica, B.M., Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 3 (2015), 356–366.
59. 59 McGuire, D.K., Van de Werf, F., Armstrong, P.W., et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol 1 (2016), 126–135.
60. 60 Gupta, A., Jelinek, H.F., Al-Aubaidy, H., Glucagon like peptide-1 and its receptor agonists: their roles in management of type 2 diabetes mellitus. Diabetes Metab Syndr, 2016 [Epub ahead of print]. doi: 10.1016/j.dsx.2016.09.003.
61. 61 Cimmaruta, D., Maiorino, M.I., Scavone, C., et al. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. Expert Opin Drug Saf 15 (2016), 77–83.
62. 62 Bunck, M.C., Corner, A., Eliasson, B., et al. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 34 (2011), 2041–2047.
63. 63 Ban, K., Noyan-Ashraf, M.H., Hoefer, J., Bolz, S.S., Drucker, D.J., Husain, M., Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117 (2008), 2340–2350.
64. 64 Drucker, D.J., The cardiovascular biology of glucagon-like peptide-1. Cell Metab 24 (2016), 15–30.
65. 65 Chilton, R., Wyatt, J., Nandish, S., Oliveros, R., Lujan, M., Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. Am J Med 124 (2011), S35–S53.
66. 66 Sokos, G.G., Nikolaidis, L.A., Mankad, S., Elahi, D., Shannon, R.P., Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12 (2006), 694–699.
67. 67 Nikolaidis, L.A., Mankad, S., Sokos, G.G., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004), 962–965.
68. 68 Lonborg, J., Vejlstrup, N., Kelbaek, H., et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 33 (2012), 1491–1499.
69. 69 Pfeffer, M.A., Claggett, B., Diaz, R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
70. 70 Kosiborod, M., Following the LEADER - why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes. J Diabetes Complications 31:2 (2017), 517–519.
71. 71 Madaan, T., Akhtar, M., Najmi, A.K., Sodium glucose CoTransporter 2 (SGLT2) inhibitors: current status and future perspective. Eur J Pharm Sci 93 (2016), 244–252.
72. 72 Abdul-Ghani, M.A., Norton, L., Defronzo, R.A., Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 32 (2011), 515–531.
73. 73 Sanchez, R.A., Sanabria, H., de Los Santos, C., Ramirez, A.J., Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease. World J Diabetes 6 (2015), 1186–1197.
74. 74 Fitchett, D., Zinman, B., Wanner, C., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 37 (2016), 1526–1534.
75. 75 Scheen, A.J., Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Res Clin Pract 121 (2016), 204–214.
76. 76 Ferrannini, E., Mark, M., Mayoux, E., CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
77. 77 Saad, M., Mahmoud, A.N., Elgendy, I.Y., et al. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: a meta-analysis of placebo-controlled randomized trials. Int J Cardiol 228 (2017), 352–358.